About Pacira
Pacira is a company based in Parsippany Troy Hills (United States) founded in 2006. Pacira has raised $85 million across 3 funding rounds from investors including Orbimed, Oxford Finance and HBM Healthcare Investments. The company has 790 employees as of December 31, 2024. Pacira has completed 3 acquisitions, including Flexion Therapeutics, GQ Bio and Myoscience. Pacira offers products and services including EXPAREL, iovera°, and ZILRETTA. Pacira operates in a competitive market with competitors including Jazz Pharmaceuticals, Lundbeck, Kriya Therapeutics, Sana Biotechnology and PureTech Health, among others.
- Headquarter Parsippany Troy Hills, United States
- Employees 790 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Pacira Biosciences, Inc.
-
Annual Revenue
$700.97 M (USD)3.85as on Dec 31, 2024
-
Net Profit
-$99.56 M (USD)-337.3as on Dec 31, 2024
-
EBITDA
$176.36 M (USD)8.26as on Dec 31, 2024
-
Total Equity Funding
$85 M (USD)
in 3 rounds
-
Latest Funding Round
$300 M (USD), Post-IPO
Mar 07, 2017
-
Investors
Orbimed
& 4 more
-
Employee Count
790
as on Dec 31, 2024
-
Investments & Acquisitions
Flexion Therapeutics
& 2 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Pacira
Pacira is a publicly listed company on the NASDAQ with ticker symbol PCRX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Pacira
Pacira offers a comprehensive portfolio of products and services, including EXPAREL, iovera°, and ZILRETTA.
Injectable suspension for managing postsurgical pain effectively.
Cold therapy device for treating acute and chronic pain.
Extended-release injectable for knee osteoarthritis pain relief.
People of Pacira
Unlock access to complete
Unlock access to complete
Leadership Team
105 people
Account Team
28 people
Software Development Team
20 people
Sales and Marketing
18 people
Senior Team
14 people
Product Management Team
13 people
Finance and Accounting
11 people
Operations Team
11 people
Unlock access to complete
Funding Insights of Pacira
Pacira has successfully raised a total of $85M across 3 strategic funding rounds. The most recent funding activity was a Post-IPO round of $300 million completed in March 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Pacira
Pacira has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Orbimed, Oxford Finance and HBM Healthcare Investments.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture debt firm focused on the life sciences sector
|
Locked | Locked | Locked | |
|
Life sciences focused VC firm funding companies in the US and Europe
|
Locked | Locked | Locked | |
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Locked | Locked | Locked |
Investor details for Pacira
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Pacira
Pacira has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include Flexion Therapeutics, GQ Bio and Myoscience.
Investment portfolio details for Pacira
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Developer of gene therapies for orthopedic treatment
|
Locked | Locked | 2012 | Locked | |
|
Developer of therapies for the treatment of musculoskeletal disorders
|
Locked | Locked | 2007 | Locked | |
|
Technology-driven dermatological products are developed and commercialized.
|
Locked | Locked | 2005 | Locked |
Complete acquisition details for Pacira
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Pacira
Detailed financials for Pacira
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Pacira Comparisons
Peer comparison for Pacira
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Pacira
Pacira operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Lundbeck, Kriya Therapeutics, Sana Biotechnology and PureTech Health, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Drugs for CNS disorders are developed and advanced.
|
|
| Locked | Locked | Locked |
Developer of therapeutic solutions for the treatment of diabetes
|
|
| Locked | Locked | Locked |
Genetically engineered cell therapies are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases.
|
|
| Locked | Locked | Locked |
Therapies for neurological and neuropsychiatric diseases are developed.
|
Detailed competitors of Pacira
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Pacira
Complete news archive for Pacira
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Pacira
Pacira was founded in 2006 and raised its 1st funding round 2 years after it was founded.
Pacira is headquartered in Parsippany Troy Hills, United States. It is registered at Parsippany Troy Hills, New Jersey, United States.
Pacira is a funded company, having raised a total of $85M across 3 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Pacira is 790.
Annual revenue of Pacira is $700.97M as on Dec 31, 2024.
Pacira was founded in 2006 and is based in Parsippany Troy Hills, United States. Injectable non-opioid pharmaceuticals for postsurgical pain management are developed, with operations centered in the healthcare sector. The lead product, EXPAREL, consists of a bupivacaine liposome injectable suspension. DepoCyt, a sustained-release liposomal cytarabine formulation, is utilized for intrathecal treatment of lymphomatous meningitis as a lymphoma complication. The domain pacira.com is maintained.
Pacira's top competitors include Jazz Pharmaceuticals, PTC Therapeutics and Biohaven Pharmaceutical.
Pacira offers EXPAREL, iovera°, and ZILRETTA.
Yes, Pacira is publicly traded on NASDAQ under the ticker symbol PCRX.
Pacira has made 3 acquisitions, including Flexion Therapeutics, GQ Bio, and Myoscience.
Pacira has 5 investors. Key investors include Orbimed, Oxford Finance, HBM Healthcare Investments, Turmeric Acquisition Corp, and Sanderling Ventures.
The ticker symbol of Pacira is PCRX on NASDAQ.